Myriad Genetics Inc (MYGN)

Dec 26, 2024

How to Take Advantage of moves in (MYGN) - Stock Traders Daily

Dec 26, 2024

Dec 24, 2024

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Intrinsic Value Is Potentially 97% Above Its Share Price - Yahoo Finance

Dec 24, 2024

Dec 22, 2024

Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Rating of "Hold" from Analysts - MarketBeat

Dec 22, 2024

Dec 22, 2024

MYGN Stock Might Gain From the New Recognition of RiskScore Study - MSN

Dec 22, 2024

Dec 21, 2024

Barclays PLC Increases Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat

Dec 21, 2024

Dec 20, 2024

PARP Inhibitor Biomarkers Market Investment Outlook: Industry - openPR

Dec 20, 2024

Dec 20, 2024

Pancreatic Cancer Market Analysis 2024: Trends, Growth, and Key - openPR

Dec 20, 2024

Dec 19, 2024

Myriad Genetics’ RiskScore Study Named One of the Top 10 - GlobeNewswire

Dec 19, 2024

Dec 19, 2024

Myriad Genetics' Breakthrough Cancer Test Named Top 10 Genomic Advance by Leading Journal - StockTitan

Dec 19, 2024

Dec 19, 2024

Hereditary Cancer Testing Market: Pioneering Early Detection and Prevention Strategies - openPR

Dec 19, 2024

Dec 19, 2024

Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics - Yahoo Finance

Dec 19, 2024

Dec 18, 2024

Myriad Genetics (NASDAQ:MYGN) Sets New 1-Year LowTime to Sell? - MarketBeat

Dec 18, 2024

Dec 18, 2024

Myriad Genetics stock hits 52-week low at $13.86 amid challenges - Investing.com Canada

Dec 18, 2024

Dec 17, 2024

Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now? - Yahoo Finance

Dec 17, 2024

Dec 17, 2024

MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm - The Eastern Progress Online

Dec 17, 2024

Dec 17, 2024

Clinical Oncology Next Generation Sequencing Market Top - openPR

Dec 17, 2024

Dec 16, 2024

How To Trade (MYGN) - Stock Traders Daily

Dec 16, 2024

Dec 15, 2024

State Street Corp Buys 359,685 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat

Dec 15, 2024

Dec 14, 2024

Myriad Genetics (NASDAQ:MYGN) Price Target Lowered to $13.00 at Bank of America - MarketBeat

Dec 14, 2024

Dec 12, 2024

Why Myriad Genetics, Inc. Shares Soared - AOL

Dec 12, 2024

Dec 11, 2024

Analysts Offer Predictions for Myriad Genetics Q1 Earnings - MarketBeat

Dec 11, 2024

Dec 10, 2024

Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing - The Manila Times

Dec 10, 2024

Dec 10, 2024

Myriad Genetics Provides Update on Discussions with - GlobeNewswire

Dec 10, 2024

Dec 10, 2024

Myriad Genetics Fights to Preserve GeneSight Coverage as UnitedHealthcare Plans 2025 Restrictions - StockTitan

Dec 10, 2024

Dec 10, 2024

Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member - The Manila Times

Dec 10, 2024

Dec 10, 2024

New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock To Gain? - Barchart

Dec 10, 2024

Dec 10, 2024

Myriad Genetics' Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines - The Manila Times

Dec 10, 2024

Dec 10, 2024

Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines - GlobeNewswire

Dec 10, 2024

Dec 10, 2024

Myriad Genetics (NASDAQ:MYGN) Stock Rating Lowered by Leerink Partnrs - MarketBeat

Dec 10, 2024

Dec 10, 2024

Myriad Genetics (NASDAQ:MYGN) Coverage Initiated by Analysts at UBS Group - MarketBeat

Dec 10, 2024

Dec 10, 2024

Disciplined Growth Investors Inc. MN Purchases 440,107 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat

Dec 10, 2024

Dec 10, 2024

New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain? - Yahoo Finance

Dec 10, 2024

Dec 10, 2024

Cancer Biopsy Market Trends, Key Drivers, and Regional Outlook - openPR

Dec 10, 2024

Dec 10, 2024

PARP Inhibitor Biomarkers Market Key Players AnalysisMyriad - openPR

Dec 10, 2024

Dec 09, 2024

Pharmacogenomics Global Market Report: Key Insights and Market - openPR

Dec 09, 2024

Dec 09, 2024

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium - The Manila Times

Dec 09, 2024

Dec 09, 2024

Myriad Genetics Unveils Breakthrough Breast Cancer Detection Tools at SABCS 2024 - StockTitan

Dec 09, 2024

Dec 09, 2024

Myriad Genetics (NASDAQ:MYGN) Stock Rating Lowered by Leerink Partners - MarketBeat

Dec 09, 2024

Dec 09, 2024

NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment - The Manila Times

Dec 09, 2024

Dec 09, 2024

NCCN Prostate Cancer Guidelines Reinforce Status of Myriad - GlobeNewswire

Dec 09, 2024

Dec 09, 2024

Myriad Genetics' Prolaris Test Retains Elite NCCN Status for 10th Year in Prostate Cancer Diagnosis - StockTitan

Dec 09, 2024

Dec 09, 2024

Wellington Management Group LLP Sells 1,545,842 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat

Dec 09, 2024

Dec 07, 2024

Myriad Genetics (NASDAQ:MYGN) Hits New 12-Month LowWhat's Next? - MarketBeat

Dec 07, 2024

Dec 07, 2024

Shareholders in Myriad Genetics (NASDAQ:MYGN) have lost 41%, as stock drops 7.0% this past week - Simply Wall St

Dec 07, 2024

Dec 07, 2024

Myriad Genetics stock hits 52-week low at $14.54 amid market shifts - Investing.com Canada

Dec 07, 2024

Dec 06, 2024

RSI Alert: Myriad Genetics (MYGN) Now Oversold - Nasdaq

Dec 06, 2024

Dec 06, 2024

Myriad Genetics stock hits 52-week low at $14.54 amid market shifts By Investing.com - Investing.com South Africa

Dec 06, 2024